Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
First Claim
Patent Images
1. A co-extruded dosage form comprising a plurality of co-extruded multilayer extrudates, each extrudate comprising:
- an extruded core comprising a matrix of an adverse agent and a hydrophobic material, wherein the hydrophobic material is present in an amount of about 30 wt % to about 99 wt % of the extruded core;
an extruded sheath comprising a hydrophobic material which surrounds at least a portion of the core, wherein the sheath is free of an adverse agent and free of an active agent, wherein the hydrophobic material is present in an amount of about 10 wt % to about 99 wt % of the extruded sheath; and
an extruded shell comprising an active agent and a hydrophobic material which surrounds at least a portion of the sheath, wherein the hydrophobic material is present in an amount of about 1 wt % to about 80 wt % of the extruded shell, and wherein the shell has a thickness of about 0.05 mm to about 3 mm;
wherein each extrudate is a portion of a multilayer extrudate sheet; and
wherein the dosage form releases about 10% or less adverse agent over a 36 hour period when subjected to an in-vitro dissolution test using USP Basket Method at 100 rpm in 700 ml simulated gastric filled at pH 1.2 without enzyme at 37°
C. for 1 hour followed by 900 ml simulated intestinal fluid at pH 7.5 without enzyme for the duration of the test.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.
45 Citations
17 Claims
-
1. A co-extruded dosage form comprising a plurality of co-extruded multilayer extrudates, each extrudate comprising:
-
an extruded core comprising a matrix of an adverse agent and a hydrophobic material, wherein the hydrophobic material is present in an amount of about 30 wt % to about 99 wt % of the extruded core; an extruded sheath comprising a hydrophobic material which surrounds at least a portion of the core, wherein the sheath is free of an adverse agent and free of an active agent, wherein the hydrophobic material is present in an amount of about 10 wt % to about 99 wt % of the extruded sheath; and an extruded shell comprising an active agent and a hydrophobic material which surrounds at least a portion of the sheath, wherein the hydrophobic material is present in an amount of about 1 wt % to about 80 wt % of the extruded shell, and wherein the shell has a thickness of about 0.05 mm to about 3 mm; wherein each extrudate is a portion of a multilayer extrudate sheet; and wherein the dosage form releases about 10% or less adverse agent over a 36 hour period when subjected to an in-vitro dissolution test using USP Basket Method at 100 rpm in 700 ml simulated gastric filled at pH 1.2 without enzyme at 37°
C. for 1 hour followed by 900 ml simulated intestinal fluid at pH 7.5 without enzyme for the duration of the test. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A co-extruded dosage form comprising:
-
a plurality of co-extruded multilayer extrudates, each extrudate comprising; an extruded core comprising a matrix of an adverse agent and a hydrophobic material; an extruded sheath comprising a hydrophobic material which surrounds at least a portion of the core, wherein the sheath is free of an adverse agent and free of an active agent; and an extruded shell comprising an active agent and a hydrophobic material which surrounds at least a portion of the sheath, wherein the extruded shell has a thickness of about 0.05 mm to about 3 mm; wherein each extrudate is a portion of a multilayer extrudate sheet, wherein each of the plurality of particles is from about 0.05 mm to about 3.0 mm in all dimensions, wherein the dosage form releases about 10% or less adverse agent over a 36 hour period when subjected to an in-vitro dissolution test using USP Basket Method at 100 rpm in 700 ml simulated gastric filled at pH 1.2 without enzyme at 37°
C. for 1 hour followed by 900 ml simulated intestinal fluid at pH 7.5 without enzyme for the duration of the test.
-
Specification